UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-19034

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

(914) 347-7000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Preferred Share Purchase Rights (1)

(Title of each class of securities covered by this Form)

Common Stock — par value $.001 per share

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)(i)	[X]	Rule 12h-3(b)(1)(i)	[   ]
Rule 12g-4(a)(1)(ii)	[   ]	Rule 12h-3(b)(1)(ii)	[   ]
Rule 12g-4(a)(2)(i)	[   ]	Rule 12h-3(b)(2)(i)	[   ]
Rule 12g-4(a)(2)(ii)	[   ]	Rule 12h-3(b)(2)(ii)	[   ]
		Rule 15d-6	[   ]

Approximate number of holders of record as of the certification or notice date: 0

(1) The Preferred Share Purchase Rights referred to herein expired on October 18, 2006, pursuant to the Rights Agreement, dated as of September 20, 1996, between Regeneron Pharmaceuticals, Inc. and Chase Mellon Shareholder Services LLC, as Rights Agent.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Regeneron Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date:     October 20, 2006	By:	/s/ Stuart Kolinski
		Stuart Kolinski
		Vice President and General Counsel